|Articles|May 5, 2003
Alcon reports findings of two moxifloxacin studies
Alcon Laboratories announced the results of two clinical studies on itsfourth-generation fluoroquinolone moxifloxacin (Vigamox). The results werepresented in a Monday morning poster session.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined
2
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
3
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
4
Clinical Experience and Integration of New Dry Eye Disease Therapies in the Clinic
5













































.png)


